Stocks Health care KLRA
NASDAQ · Health careKailera Therapeutics, Inc. (KLRA)
At June 30, 2026 it held $130.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
What Kailera Therapeutics, Inc. does
Kailera Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KLRA.
Latest SEC filings
What Kailera Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026
- August 12, 2026
- August 5, 2026Passive stake (5% or more) SCHEDULE 13G
- May 26, 2026Quarterly report 10-Q · period to March 31, 2026
- May 26, 2026
- April 23, 2026Activist stake (5% or more) SCHEDULE 13D
- April 23, 2026Activist stake (5% or more) SCHEDULE 13D
- April 20, 2026
Questions about KLRA
What does Kailera Therapeutics, Inc. do?
Kailera Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KLRA.
When did Kailera Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 9, 2026.
Similar companies
Follow KLRA
Get an email when Kailera Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow KLRA: get an email when it filesWhere the numbers come from
Financial figures are the values Kailera Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.